Avibactam Sodium

Non-β-Lactam β-Lactamase Inhibitor for Multidrug-Resistant Gram-Negative Infections

Product Details

CAS Number: 1192491-61-4
Standard: In-house Standard

Avibactam Sodium is a highly effective non-β-lactam β-lactamase inhibitor designed for use in combination with selected cephalosporins or carbapenems. It significantly enhances antibiotic efficacy against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections.

As a specialized API manufacturer, we provide Avibactam Sodium with stable quality, high purity, and full regulatory documentation to support global pharmaceutical formulations.

Applications

1. Overcoming Antibiotic Resistance

Avibactam Sodium effectively inhibits key β-lactamase families-including Class A (eg, KPC), Class C (AmpC), and selected Class D enzymes-which are responsible for resistance to β-lactam antibiotics. When combined with cephalosporins or carbapenems, it restores antimicrobial activity against resistant Gram-negative pathogens.

2. Treatment of Hospital-Acquired Infections

Hospital-acquired infections often involve highly resistant organisms such as Pseudomonas aeruginosa , Acinetobacter baumannii , and MDR Enterobacteriaceae. Used with ceftazidime or ceftaroline, Avibactam Sodium provides enhanced clinical efficacy by overcoming β-lactamase-mediated resistance, making it valuable for critically ill patients in intensive care settings.

3. Complicated Intra-Abdominal Infections (cIAIs)

The ceftazidime–avibactam combination demonstrates strong activity against mixed aerobic/anaerobic pathogens and resistant Enterobacteriaceae. Avibactam prevents enzymatic degradation of ceftazidime, expanding the antibacterial spectrum and improving treatment outcomes in cIAIs.

4. Complicated Urinary Tract Infections (cUTIs)

Avibactam-containing regimens show high effectiveness in treating cUTIs caused by resistant E. coli and Klebsiella pneumoniae . This therapy offers a reliable option when conventional antibiotics fail, reducing recurrence risk and improving patient recovery.

Conclusion

Avibactam Sodium is a critical API for combating antimicrobial resistance. By restoring the potency of β-lactam antibiotics, it plays an indispensable role in the treatment of hospital-acquired infections, cIAIs, and cUTIs.